IP Library Granted Patent US 9,688,982
Granted Patent B2
US 9,688,982 · App. 14/052,621 · Granted Jun 27, 2017

Methods and compositions for the treatment of cancer or other diseases

Inventors: Hua Yu (Glendora, CA); Marcin Kortylewski (Monrovia, CA); Richard Jove (Glendora, CA); Piotr Marek Swiderski (San Dimas, CA); John J. Rossi (Alta Loma, CA)
Assignee: CITY OF HOPE
C12N15/113A61K31/713A61K31/7105A61K47/481A61K47/48092C07H21/02C07K14/47C12N15/1135
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,688,982
App. No.
14/052,621
Granted
Jun 27, 2017
Kind
B2
Abstract

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.

Claims (6)

1. A molecule comprising a first oligonucleotide moiety covalently bound to a first oligonucleotide through a first spacer, wherein:

(i) said first oligonucleotide is hybridized to a second complementary oligonucleotide, wherein said second complementary oligonucleotide is covalently bound to a dsRNA through a second spacer, wherein said second complementary oligonucleotide and the complementary portion of said first oligonucleotide comprise 2′-fluoro, 2′-O-methyl or locked nucleic acid; and

(iii) said first spacer and said second spacer consist of one or more C3 spacers, wherein said dsRNA is an siRNA and said first oligonucleotide moiety comprises an aptamer.

2. The molecule of claim 1 , wherein the first oligonucleotide moiety is capable of delivering the molecule to a cell of interest.

3. The molecule of claim 2 , wherein the dsRNA is capable of treating a disease.

4. The molecule of claim 3 , wherein the disease is selected from the group consisting of cancer, an infectious disease, an autoimmune disease, a disease due to excessive angiogenesis and/or a disease benefitting from increased angiogenesis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014
From: YU, HUA; KORTYLEWSKI, MARCIN; JOVE, RICHARD; SWIDERSKI, PIOTR MAREK; ROSSI, JOHN J
To: CITY OF HOPE
Reel/Frame 032740/0562 →
Continuity (7)
Continuation 13229146 · Sep 9, 2011
Continuation In Part 12879199 · Sep 10, 2010
Continuation In Part 11966423 · Dec 28, 2007
Provisional Application 61466086 · Mar 22, 2011
Provisional Application 61241764 · Sep 11, 2009
Provisional Application 60897495 · Jan 26, 2007
Related Publication 20140066592A1 · Mar 6, 2014